MCM
BBIO icon

Manchester Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Manchester Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149 Buy
+2
New +$140 ﹤0.01% 1294
2022
Q1 		– Sell
-253
Closed -$4K – 1029
2021
Q4 		$4K Hold
253
– – ﹤0.01% 704
2021
Q3 		$12K Buy
+253
New +$13.6K ﹤0.01% 567

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Manchester Capital Management's BBIO Position: Q2 2026 in Review

Manchester Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2 shares worth $149. The stake represents ﹤0.01% of the portfolio and ranks #1294 among its holdings. This is a return to the name: Manchester Capital Management previously reported a position in BBIO as recently as Q4 2021.

Manchester Capital Management first reported a position in BBIO in Q3 2021 and has held it in 3 quarters since. The position peaked at $12K in Q3 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Manchester Capital Management held 2 shares of BridgeBio Pharma worth $149 as of Q2 2026.
  • BridgeBio Pharma was a new Manchester Capital Management position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1294 holding.
  • Manchester Capital Management first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 3 quarters since.
  • Manchester Capital Management's BridgeBio Pharma position peaked at $12K in Q3 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.